Trials / Recruiting
RecruitingNCT07269145
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is the first-in-human clinical study of TQB3122, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3122 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3122 Capsules | TQB3122 Capsules is a poly(ADP - ribose) polymerase 1 (PARP1) -targeted inhibitor. |
Timeline
- Start date
- 2026-01-22
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2025-12-08
- Last updated
- 2026-01-28
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07269145. Inclusion in this directory is not an endorsement.